Please assess the completion status of the following clinical trial:

Trial Title: A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, 18-65 years of age;~* locally recurrent and metastatic breast cancer;~* measurable or evaluable disease;~* ECOG performance status of 0-2;~* LVEF \>=50% without clinical symptoms or signs of heart failure.~Exclusion Criteria:~* unknown HER2 status, or known HER2-positive status;~* prior chemotherapy for locally recurrent or metastatic disease;~* prior adjuvant or neoadjuvant taxane therapy within 12 months prior to start of treatment;~* clinical or radiological evidence of CNS metastases;~* clinically significant cardiovascular disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).